Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a tumor-zapping procedure also wake up the immune system?

NCT ID NCT04892810

Knowledge-focused Sponsor: University Hospital, Grenoble Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 22, 2026 · Last updated Jul 23, 2026 · Updated 1 time

Summary

This study looks at how two heat-based procedures — radiofrequency ablation and microwave ablation — affect the immune system in people with small liver cancers. Researchers will take blood samples and tissue biopsies before and after treatment to track changes in immune cells. The goal is to understand whether one method triggers a stronger immune response than the other.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
percutaneous ablation (radiofrequency or microwave)
What this could lead to
If the immune response differs between the two ablation methods, it could point toward ways to boost the body's own fight against liver cancer.
What could go wrong
This is a very small, early observational study — it is not designed to test a treatment's effectiveness, and any immune changes seen may not lead to better outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

20 people

The number who actually took part.

Started

Feb 2022

Finished

Jun 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients older than 40 years old that can benefit for ablation (either RFA or MWA) for HCC

Ages

40 years and older

Sex

Anyone

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Histologically proven HCC for less than 3 months before ablation * Decision of ablation treatment in multidisciplinary meeting Exclusion Criteria: * Fibrolamellar HCC * Hepatocholangiocarcinoma

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Hepatocellular carcinoma are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hepatocellular carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Hepatocellular carcinoma

Contacts and locations

Locations

  • CHU Grenoble Alpes

    Grenoble, 38043, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.